DE

460.88

+0.05%↑

CTAS

198.8

-0.16%↓

FDX

240.24

-0.95%↓

PAYX

126.51

-0.29%↓

CPRT

44.93

+1.65%↑

DE

460.88

+0.05%↑

CTAS

198.8

-0.16%↓

FDX

240.24

-0.95%↓

PAYX

126.51

-0.29%↓

CPRT

44.93

+1.65%↑

DE

460.88

+0.05%↑

CTAS

198.8

-0.16%↓

FDX

240.24

-0.95%↓

PAYX

126.51

-0.29%↓

CPRT

44.93

+1.65%↑

DE

460.88

+0.05%↑

CTAS

198.8

-0.16%↓

FDX

240.24

-0.95%↓

PAYX

126.51

-0.29%↓

CPRT

44.93

+1.65%↑

DE

460.88

+0.05%↑

CTAS

198.8

-0.16%↓

FDX

240.24

-0.95%↓

PAYX

126.51

-0.29%↓

CPRT

44.93

+1.65%↑

Search

Ocugen Inc

Suletud

1.78 1.71

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

1.76

Max

1.87

Põhinäitajad

By Trading Economics

Sissetulek

611K

-15M

Müük

-108K

1.4M

Kasumimarginaal

-1,073.489

Töötajad

95

EBITDA

724K

-13M

Soovitused

By TipRanks

Soovitused

Tugev "osta" hinnang

12 kuu keskmine prognoos

+367.03% upside

Dividendid

By Dow Jones

Järgmine tulemuste avaldamine

7. nov 2025

Turustatistika

By TradingEconomics

Turukapital

138M

456M

Eelmine avamishind

0.07

Eelmine sulgemishind

1.78

Tehniline skoor

By Trading Central

Kindlus

Strong Bearish Evidence

Ocugen Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

7. okt 2025, 16:58 UTC

Tulu

BMW Trims 2025 View, Citing Weaker Performance in China

7. okt 2025, 23:43 UTC

Market Talk

Nikkei May Trade Rangebound; Takaichi's Policy Steps in Focus -- Market Talk

7. okt 2025, 23:36 UTC

Market Talk

Gold Edges Higher, Supported by Possible Hedging Demand -- Market Talk

7. okt 2025, 23:19 UTC

Market Talk

Veem Can Secure More Defense Deals Following Northrop Grumman Win -- Market Talk

7. okt 2025, 22:50 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

7. okt 2025, 22:50 UTC

Market Talk

RBNZ Should Take the Option of a Bigger Cut -- Market Talk

7. okt 2025, 22:40 UTC

Market Talk

South32's Alaskan Project Seen Starting Sooner, Worth More After U.S. Deal -- Market Talk

7. okt 2025, 21:56 UTC

Market Talk

Global Equities Roundup: Market Talk

7. okt 2025, 21:56 UTC

Market Talk

Australia Shares Set to Start Day Roughly Flat -- Market Talk

7. okt 2025, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

7. okt 2025, 20:44 UTC

Kuumad aktsiad

Stocks to Watch Tuesday Recap: Oracle, Dell, Trilogy Metals -- WSJ

7. okt 2025, 19:42 UTC

Market Talk

Treasury Yields Fall as Data Blackout Continues -- Market Talk

7. okt 2025, 19:23 UTC

Omandamised, ülevõtmised, äriostud

Private-Equity Stocks Have Gotten Crushed. J.P. Morgan Says This One Is a Buy. -- Barrons.com

7. okt 2025, 19:07 UTC

Market Talk

Oil Futures Settle Mixed With Higher OPEC+ Supply in View -- Market Talk

7. okt 2025, 19:02 UTC

Market Talk

U.S. Natural Gas Posts Back-to-Back Gains -- Market Talk

7. okt 2025, 16:20 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

7. okt 2025, 16:20 UTC

Market Talk

Basic Materials Roundup: Market Talk

7. okt 2025, 16:20 UTC

Market Talk

Home Depot Extended Pro Desk Hours Could Drive Sales Growth -- Market Talk

7. okt 2025, 16:15 UTC

Market Talk

AMD's OpenAI Deal Resets Competitive Landscape for Chips -- Market Talk

7. okt 2025, 16:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

7. okt 2025, 15:37 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

7. okt 2025, 15:37 UTC

Market Talk

Markets for Canadian Aluminum Open Up Beyond U.S. -- Market Talk

7. okt 2025, 15:33 UTC

Market Talk

Gold Rise Tied to Lower Confidence in Dollar Assets -- Market Talk

7. okt 2025, 15:25 UTC

Market Talk

Canadian Mining Stocks Rally on U.S. Defense Dept. Deal -- Market Talk

7. okt 2025, 15:15 UTC

Market Talk

Investors Look to Gold, Bitcoin as Traditional Correlations Break Down -- Market Talk

7. okt 2025, 15:04 UTC

Market Talk

Market Talk Roundup: Latest on U.S. Politics

7. okt 2025, 15:04 UTC

Market Talk

Canadian Aluminum Exports Squeezed by Tariffs -- Market Talk

7. okt 2025, 14:56 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

7. okt 2025, 14:56 UTC

Market Talk

U.S. Government Shutdown May Impact Release of Canadian Trade Data -- Market Talk

7. okt 2025, 14:52 UTC

Tulu

These Stocks Are Moving the Most Today: Tesla, AMD, Ford, Dell, IBM, AppLovin, Trilogy Metals, Aehr, and More -- Barrons.com

Võrdlus sarnastega

Hinnamuutus

Ocugen Inc Prognoos

Hinnasiht

By TipRanks

367.03% tõus

12 kuu keskmine prognoos

Keskmine 8.5 USD  367.03%

Kõrge 15 USD

Madal 4 USD

Põhineb 4 Wall Streeti analüütiku instrumendi Ocugen Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

4 ratings

4

Osta

0

Hoia

0

Müü

Tehniline skoor

By Trading Central

0.6818 / 0.74Toetus ja vastupanu

Lühikene perspektiiv

Strong Bearish Evidence

Keskpikk perspektiiv

Strong Bullish Evidence

Pikk perspektiiv

No Evidence

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest Ocugen Inc

Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve patients' health. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, currently under Phase 3 trials for the treatment of retinitis pigmentosa and Phase 1/2 trials for the treatment of leber congenital amaurosis; OCU410, a gene therapy under phase 1/2 for the treatment of dry age-related macular degeneration (AMD); and OCU410ST, a gene therapy under phase 1/2 for the treatment of Stargardt disease. It is also involved in the development of OCU200, a novel fusion protein that is in preclinical development stage for the treatment of diabetic macular edema, diabetic retinopathy, and wet age-related macular degeneration; and NeoCart, an autologous chondrocyte-derived neocartilage, currently under Phase 3 studies indicated for the repair of knee cartilage injuries in adult. In addition, the company is developing OCU500, a COVID-19 vaccine; OCU510, a seasonal quadrivalent flu vaccine; and OCU520, a combination quadrivalent seasonal flu and COVID-19 vaccine. It has collaboration agreements with National Institute of Allergy and Infectious Diseases for early clinical studies for the OCU500 program; and a strategic partnership with CanSino Biologics Inc. for manufacturing its modifier gene therapy pipeline product candidates. The company was founded in 2013 and is headquartered in Malvern, Pennsylvania.
help-icon Live chat